Drug intelligence / Profile preview

ICP-B03

Development stage: Preclinical
Lead developer: InnoCare Pharma
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes

Overview

ICP-B03 is a preclinical **tumor-conditional pro-interleukin-15 biologic** being developed by InnoCare for cancer treatment. It is designed as an IL-15 replacement therapy that is conditionally activated within the tumor microenvironment, with the goal of selectively stimulating antitumor immune cells while limiting peripheral cytokine activity. The program is being investigated primarily for **solid tumors**, including **digestive system malignancies**, and represents an immuno-oncology cytokine approach intended to enhance local antitumor immune responses.

Other names: tumor-conditional pro-interleukin-15 biologic

Targets

IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)

Beyond the preview

Go deeper on ICP-B03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICP-B03.

Explore the full profile